{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:37Z","timestamp":1790697937805,"version":"4.1.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To compare the visual acuity (VA) outcomes and dosing intervals of faricimab with those of other antivascular endothelial growth factor agents in treatment-na\u00efve and treatment-experienced eyes with neovascular age-related macular degeneration (nAMD).\n                    <jats:bold>Methods:<\/jats:bold>\n                    De-identified electronic medical records (Vestrum Health treatment and outcomes database) of patients with nAMD treated with bevacizumab, ranibizumab, aflibercept, or faricimab between January 2021 and December 2023 were included. Mean VA change and mean number of days between injections were collected through 6 injections for treatment-na\u00efve eyes and through 2 injections for treatment-switched eyes.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 736 treatment-na\u00efve eyes receiving faricimab experienced nonsignificantly lower VA gains than all other drugs; 5467 eyes switched to faricimab demonstrated lower VA gains relative to other drugs. This includes significantly lower gains than aflibercept or bevacizumab when switched from ranibizumab (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .01). Bevacizumab achieved the highest VA gains\u2014significantly more than aflibercept (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .01) in the treatment-na\u00efve cohort and significantly more than faricimab and aflibercept when switched from ranibizumab (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .01). After adjusting for significant VA differences at baseline and at the switch date, all drugs displayed similar VA gains in both cohorts. Compared with all other drugs, faricimab provided up to 4 additional days on average between injections and had the highest proportion of eyes extended over 50 days between the final 2 injections for both cohorts. Relative to aflibercept and ranibizumab, these injection frequencies for faricimab were significantly longer (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .01).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Treatment-na\u00efve and treatment-experienced nAMD eyes receiving faricimab demonstrated VA gains and minimally longer injection intervals, comparable to other antivascular endothelial growth factor agents.\n                  <\/jats:p>","DOI":"10.1177\/24741264261428749","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:02:20Z","timestamp":1775786540000},"page":"593-601","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-154X","authenticated-orcid":false,"given":"Lucas W.","family":"Rowe","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7226-1615","authenticated-orcid":false,"given":"Nathan N.","family":"Macha","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Retina Partners Midwest, and Midwest Eye Institute, Carmel, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Martin Health, Cleveland Clinic Florida, Stuart, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-1846","authenticated-orcid":false,"given":"Raj K.","family":"Maturi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Retina Partners Midwest, and Midwest Eye Institute, Carmel, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.19"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.06.004"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.03.021"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081869"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"e_1_3_3_14_2","unstructured":"Patel PJ Talks J Salvo G De LA Pearce I De Silva SR. Real-world use of faricimab to treat nAMD patients in the UK (FARWIDE study). Paper presented at: American Society of Retinal Specialists Annual Meeting; Seattle; 2023."},{"issue":"7","key":"e_1_3_3_15_2","first-page":"4905","article-title":"Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD","volume":"65","author":"Varma D","year":"2024","unstructured":"Varma D, Talks J, de Salvo G, et al. Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD. Invest Ophthalmol Vis Sci. 2024;65(7):4905.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"e_1_3_3_16_2","first-page":"2113","article-title":"Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: the FARETINA-AMD study","volume":"65","author":"Tabano D","year":"2024","unstructured":"Tabano D, Ko S, Borkar D, et al. Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: the FARETINA-AMD study. Invest Ophthalmol Vis Sci. 2024;65(7):2113.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"e_1_3_3_17_2","first-page":"2218","article-title":"FARETINA-AMD-Early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM analysis","volume":"64","author":"Borkar DS","year":"2023","unstructured":"Borkar DS, Tabano D, Garmo V, et al. FARETINA-AMD-Early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM analysis. Invest Ophthalmol Vis Sci. 2023;64(8):2218.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261428749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261428749","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261428749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:26:09Z","timestamp":1790695569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261428749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/24741264261428749"],"URL":"https:\/\/doi.org\/10.1177\/24741264261428749","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}